SCHEMBL2642353

SCHEMBL2642353

FC(F)c1cccnc1Cl

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 1/20 0.41
CYP2C19 P33261 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
KCNA5 P22460 3/20 0.35
CYP2D6 P10635 1/20 0.34
HRH1 P35367 1/20 0.34
KCNH2 Q12809 1/20 0.34
RAB9A P51151 2/20 0.33
P2RX7 Q99572 1/20 0.33
MPI P34949 1/20 0.33
HTT P42858 1/20 0.33
TRPV4 Q9HBA0 1/20 0.33
FAAH O00519 3/20 0.33
KCND3 Q9UK17 1/20 0.33
NFE2L2 Q16236 1/20 0.33
NPC1 O15118 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30783229 1.00 SMN1; SMN2 (0.41) SMN1; SMN2LMNACYP2C19TDP1KCNA5
SCHEMBL23489744 0.79 SMN1; SMN2 (0.40) SMN1; SMN2LMNACYP2C19KCNA5RAB9A
SCHEMBL4985875 0.79 SMN1; SMN2 (0.42) SMN1; SMN2LMNACYP2C19TDP1KCNA5
SCHEMBL25971609 0.77 SMN1; SMN2 (0.45) SMN1; SMN2LMNACYP2C19TDP1KCNA5
SCHEMBL2363024 0.77 GABRA1 (0.43) SMN1; SMN2LMNACYP2C19TDP1KCNA5
SCHEMBL950804 0.77 SMN1; SMN2 (0.45) SMN1; SMN2LMNACYP2C19TDP1KCNA5
SCHEMBL16307663 0.74 NAPRT (0.42) SMN1; SMN2LMNATDP1CYP2D6HRH1
SCHEMBL29743319 0.74 TRIM24 (0.43) SMN1; SMN2LMNACYP2C19TDP1CYP2D6
SCHEMBL16838712 0.74 TRIM24 (0.43) SMN1; SMN2LMNACYP2C19TDP1CYP2D6
SCHEMBL998722 0.74 SMN1; SMN2 (0.42) SMN1; SMN2LMNACYP2C19KCNA5CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109641870-A Substituted halo (thio) acyl compounds 拜耳作物科学股份公司 2019-04-16 CN claimed
EP-4745134-A1 PROTEIN ARGINASE METHYLTRANSFERASE-5 INHIBITOR AND MEDICAL USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2026-05-20 EP disclosed
US-20260125364-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2026-05-07 US disclosed
WO-2025111547-A1 2,3-DIHYDROPYROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF RGENTA THERAPEUTICS, INC. (US) 2025-05-30 WO disclosed
US-20250049772-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-02-13 US disclosed
WO-2025016323-A1 PROTEIN ARGINASE METHYLTRANSFERASE-5 INHIBITOR AND MEDICAL USE THEREOF 江苏亚虹医药科技股份有限公司 2025-01-23 WO disclosed
US-20240317713-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2024-09-26 US disclosed
US-12005054-B2 Piperidinyl-3-(aryloxy)propanamides and propanoates TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-06-11 US disclosed
US-11964961-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2024-04-23 US disclosed
CN-112236423-B Piperidinyl-3- (aryloxy) propanamides and propionic acid esters 武田药品工业株式会社 2024-02-06 CN disclosed
US-7687502-B2 Substituted quinazoline or pyridopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-03-30 US disclosed
US-20080070894-A1 Novel Substituted Imidazole Derivative MSD K.K. (JP) 2008-03-20 US disclosed
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative MSD K.K. (JP) 2008-02-07 US disclosed
CN-101048406-A Novel substituted imidazole derivatives BANYU PHARMA CO LTD (JP) 2007-10-03 CN disclosed
EP-1790650-A1 NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-05-30 EP disclosed
CN-1934100-A Substituted quinazoline or pyridopyrimidine derivatives BANYU PHARMA CO LTD (JP) 2007-03-21 CN disclosed
EP-1734040-A1 SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-12-20 EP disclosed
EP-0281110-B1 N-[2-(pyridyl)propyl]-N-substituted sulfonamide, herbicide containing the same as an active ingredient and intermediate thereof MITSUBISHI CHEM IND (JP) 1994-09-07 EP disclosed
US-4960897-A Herbicide containing 1-(halogenomethyl)-vinyl pyridines MITSUBISHI KASEI CORPORATION (JP) 1990-10-02 US disclosed
EP-0281110-A2 N-[2-(pyridyl)propyl]-N-substituted sulfonamide, herbicide containing the same as an active ingredient and intermediate thereof MITSUBISHI KASEI CORPORATION (JP) 1988-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070894-A1 Novel Substituted Imidazole Derivative PLK1, CDK1, CDK11A SMN1; SMN2 3452/4885LMNA 2017/4885CYP2C19 2687/4885
US-20260125364-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS HTR6, HTR3C, OPRD1 SMN1; SMN2 614/4885LMNA 2257/4885CYP2C19 1061/4885
US-11964961-B2 Heteroaromatic compounds and their use as dopamine D1 ligands DRD2, DRD1, HTR1D SMN1; SMN2 1161/4885LMNA 2789/4885CYP2C19 597/4885
US-12005054-B2 Piperidinyl-3-(aryloxy)propanamides and propanoates SSTR4, SSTR3, NPY4R SMN1; SMN2 933/4885LMNA 2601/4885CYP2C19 651/4885
US-20250049772-A1 PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES SSTR4, SSTR3, NPY4R SMN1; SMN2 933/4885LMNA 2601/4885CYP2C19 651/4885
US-20240317713-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD2, DRD1, HTR1D SMN1; SMN2 1161/4885LMNA 2789/4885CYP2C19 597/4885
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative GCK, GCKR, PDXK SMN1; SMN2 4213/4885LMNA 4577/4885CYP2C19 481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.